NO20063261L - Selektive peroksisome proliferatoraktiviterte reseptormodulatorer - Google Patents

Selektive peroksisome proliferatoraktiviterte reseptormodulatorer

Info

Publication number
NO20063261L
NO20063261L NO20063261A NO20063261A NO20063261L NO 20063261 L NO20063261 L NO 20063261L NO 20063261 A NO20063261 A NO 20063261A NO 20063261 A NO20063261 A NO 20063261A NO 20063261 L NO20063261 L NO 20063261L
Authority
NO
Norway
Prior art keywords
activated receptor
peroxisome proliferator
receptor modulators
syndrome
compound
Prior art date
Application number
NO20063261A
Other languages
English (en)
Inventor
Rafael Ferritto-Crespo
Maria Delores Martin-Or Finger
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20063261L publication Critical patent/NO20063261L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)

Abstract

Foreliggende oppfinnelse angår en ny forbindelse, dens sammensetning og anvendelse av en forbindelse som har stnikturforrnel (I), eller et farmasøytisk akseptabelt salt, solvat, hydrat eller stereoisomerer derav, som er anvendelige ved behandling eller hindring av forstyrrelser mediert av en peroksisom proliferator aktivert reseptor (PPAR), slik som syndrom X, type II diabetes, hyperglykemi, hyperlipidemi, fedme, koagaulopati, hypertensjon, arteriosklerose og andre forstyrrelser relatert til syndrom X og kardiovaskulære sykdommer.
NO20063261A 2003-12-15 2006-07-13 Selektive peroksisome proliferatoraktiviterte reseptormodulatorer NO20063261L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03380288 2003-12-15
US55063604P 2004-03-05 2004-03-05
PCT/US2004/038232 WO2005061441A1 (en) 2003-12-15 2004-12-08 Selective peroxisome proliferator activated receptor modulators

Publications (1)

Publication Number Publication Date
NO20063261L true NO20063261L (no) 2006-09-06

Family

ID=34712592

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063261A NO20063261L (no) 2003-12-15 2006-07-13 Selektive peroksisome proliferatoraktiviterte reseptormodulatorer

Country Status (26)

Country Link
US (1) US7321056B2 (no)
EP (1) EP1697306B1 (no)
JP (1) JP2007516267A (no)
KR (1) KR100806004B1 (no)
CN (1) CN1886364A (no)
AT (1) ATE368026T1 (no)
AU (1) AU2004303793A1 (no)
BR (1) BRPI0417401A (no)
CA (1) CA2549008A1 (no)
CY (1) CY1106846T1 (no)
DE (1) DE602004007825T2 (no)
DK (1) DK1697306T3 (no)
EA (1) EA009023B1 (no)
EC (1) ECSP066639A (no)
ES (1) ES2289589T3 (no)
HK (1) HK1097406A1 (no)
HR (1) HRP20070422T3 (no)
IL (1) IL175997A0 (no)
MA (1) MA28399B1 (no)
MX (1) MXPA06006829A (no)
NO (1) NO20063261L (no)
PL (1) PL1697306T3 (no)
PT (1) PT1697306E (no)
SI (1) SI1697306T1 (no)
WO (1) WO2005061441A1 (no)
ZA (1) ZA200604834B (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013049621A1 (en) * 2011-09-29 2013-04-04 The Board Of Regents Of The University Of Oklahoma Ophthalmic compositions comprising ppar-alpha agonists and methods of production and use thereof
CN106310173A (zh) * 2016-08-24 2017-01-11 厦门三川利生物科技有限公司 含过氧化物酶体增殖物激活受体多维果酸醇及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
WO2000061582A1 (fr) * 1999-04-08 2000-10-19 Sankyo Company, Limited Derives imidazole condenses substitues
WO2002044127A1 (fr) * 2000-11-29 2002-06-06 Kyorin Pharmaceutical Co., Ltd. Dérivés d'acide carboxylique substitué
WO2002083616A1 (fr) * 2001-04-10 2002-10-24 Sankyo Company, Limited DERIVE D'ACIDE GRAS φomega;-ARYLE α-SUBSTITUE
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0314079D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
EP1517882A1 (en) * 2002-06-19 2005-03-30 Eli Lilly And Company Amide linker peroxisome proliferator activated receptor modulators

Also Published As

Publication number Publication date
US7321056B2 (en) 2008-01-22
IL175997A0 (en) 2006-10-05
ATE368026T1 (de) 2007-08-15
HRP20070422T3 (en) 2007-11-30
CY1106846T1 (el) 2012-05-23
PT1697306E (pt) 2007-10-19
CN1886364A (zh) 2006-12-27
DE602004007825D1 (de) 2007-09-06
ECSP066639A (es) 2006-10-25
ES2289589T3 (es) 2008-02-01
WO2005061441A1 (en) 2005-07-07
PL1697306T3 (pl) 2007-11-30
MXPA06006829A (es) 2006-08-23
KR100806004B1 (ko) 2008-02-26
EP1697306A1 (en) 2006-09-06
ZA200604834B (en) 2007-11-28
JP2007516267A (ja) 2007-06-21
HK1097406A1 (en) 2007-06-22
DK1697306T3 (da) 2007-11-12
SI1697306T1 (sl) 2008-02-29
DE602004007825T2 (de) 2008-04-17
BRPI0417401A (pt) 2007-05-08
US20070066683A1 (en) 2007-03-22
MA28399B1 (fr) 2007-01-02
CA2549008A1 (en) 2005-07-07
KR20060121192A (ko) 2006-11-28
EA009023B1 (ru) 2007-10-26
AU2004303793A1 (en) 2005-07-07
EA200601159A1 (ru) 2006-10-27
EP1697306B1 (en) 2007-07-25

Similar Documents

Publication Publication Date Title
ATE386715T1 (de) Modulatoren des peroxisomproliferatoraktivierten rezeptors
BRPI0407180A (pt) Composto, composição farmacêutica, métodos para modular um receptor ativado pelo proliferador de peroxissoma, para tratar ou prevenir uma doença ou condição, para diminuir a glicose no sangue em um mamìfero, para tratar ou prevenir diabetes mellitus, doença cardiovascular e sìndrome x em um mamìfero, e, uso de um composto
NO20074117L (no) Fremgangsmater og sammensetninger for a behandle diabetes, metabolske sykdommer og tilstander
BR0210167A (pt) Composto, composição farmacêutica, métodos para modular um receptor ativado com proliferador de peroxissoma, para tratar ou prevenir uma doença ou condição e para abaixar a glicose no sangue, e, uso de um composto
NO20084318L (no) Inhibitorer av II-beta-hydroksystereoid dehydrogenase I
NO20032861L (no) Heteroarylurea nevropeptid Y Y5-reseptorantagonister
NO20065984L (no) Forbindelser og sammensetninger som PPAR modulatorer
NO20084874L (no) Piendinylsubstituerte pyrrolidinoner som hemmere av 11-beta-hydroksysteroiddehydrogenase 1
NO20076479L (no) Nye oksadiazolderivater og anvendelse derav som positive allosteriske metabotropiske modulatorer av glutamatreseptorer
NO20076478L (no) Substituerte oksadiazolderivater som positive allosteriske modulatorer av metabotrope glutamatreseptorer
NO20083562L (no) Cannabinoidreseptormodulatorer
ATE539743T1 (de) Verfahren zur prävention und behandlung von ppar- vermittelten zuständen mit macelignan
NO20074670L (no) Indolforbindelser og anvendelse derav
EA200800081A1 (ru) Бензамидные производные (варианты), содержащая их фармацевтическая композиция (варианты), способ лечения заболеваний, связанных с модуляцией гидроксистероиддегидрогеназ на основе указанных производных(варианты)
NO20084364L (no) Azetidin derivater som G-protein koblet reseptor (GPR119) agonister
NO20084919L (no) Oksadiazolidindionforbindelse
NO20074390L (no) Forsterket bimatoprost oye-opplosning
MA30201B1 (fr) Derives triazoliques comme inhibiteurs de la 11-beta-hydroxysteroide dehydrogenase-1
NO20070258L (no) Benzyltriazolonforbindelser som ikke-nukleoside revers transkriptase inhibitorer
NO20065926L (no) Substituerte oksazolbenzoisotiazoldioksidderivater samt fremgangsmate for fremstilling og anvendelse derav
RU2017139870A (ru) Новые агонисты npr-b
NO20062511L (no) Fenoksy-eddiksyrederivater anvendelige som peroksisomproliferator-aktiverende reseptor (PPAR) dualagonister
EA200500054A1 (ru) Новые соединения, применимые для лечения ожирения, сахарного диабета ii типа и расстройств центральной нервной системы
NO20083065L (no) Nye N-sulfamoylpiperidinamider for profylakse eller behandling av overvekt og beslektede tilstander
NO20083036L (no) Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av depresjon

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application